151 related articles for article (PubMed ID: 33876360)
1. Palpable Adenopathy Does Not Indicate High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer.
Crown A; Sevilimedu V; Morrow M
Ann Surg Oncol; 2021 Oct; 28(11):6060-6068. PubMed ID: 33876360
[TBL] [Abstract][Full Text] [Related]
2. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
[TBL] [Abstract][Full Text] [Related]
3. Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer.
Weber WP; Matrai Z; Hayoz S; Tausch C; Henke G; Zimmermann F; Montagna G; Fitzal F; Gnant M; Ruhstaller T; Muenst S; Mueller A; Lelièvre L; Heil J; Knauer M; Egle D; Sávolt Á; Heidinger M; Kurzeder C; ; Zwahlen DR; Gruber G; Ackerknecht M; Kuemmel S; Bjelic-Radisic V; Smanykó V; Vrieling C; Satler R; Hagen D; Becciolini C; Bucher S; Simonson C; Fehr PM; Gabriel N; Maráz R; Sarlos D; Dedes KJ; Leo C; Berclaz G; Fansa H; Hager C; Reisenberger K; Singer CF; Loibl S; Winkler J; Lam GT; Fehr MK; Kohlik M; Clerc K; Ostapenko V; Maggi N; Schulz A; Andreozzi M; Goldschmidt M; Saccilotto R; Markellou P
JAMA Surg; 2023 Oct; 158(10):1013-1021. PubMed ID: 37466971
[TBL] [Abstract][Full Text] [Related]
4. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
[TBL] [Abstract][Full Text] [Related]
5. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
6. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
Tvedskov TF
Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
[TBL] [Abstract][Full Text] [Related]
7. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
8. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
[TBL] [Abstract][Full Text] [Related]
9. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
[TBL] [Abstract][Full Text] [Related]
10. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
[TBL] [Abstract][Full Text] [Related]
11. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Burden of Nodal Disease for Breast Cancer Patients with Clinically Positive Nodes: Hope for More Limited Axillary Surgery.
Angarita S; Ye L; Rünger D; Hadaya J; Baker JL; Dawson N; Thompson CK; Lee MK; Attai DJ; DiNome ML
Ann Surg Oncol; 2021 May; 28(5):2609-2618. PubMed ID: 33084993
[TBL] [Abstract][Full Text] [Related]
13. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.
Kantor O; Weiss A; Burstein HJ; Mittendorf EA; King TA
Ann Surg Oncol; 2022 Nov; 29(12):7674-7682. PubMed ID: 35763229
[TBL] [Abstract][Full Text] [Related]
14. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
Tadros AB; Moo TA; Stempel M; Zabor EC; Khan AJ; Morrow M
Breast Cancer Res Treat; 2020 Feb; 180(1):197-205. PubMed ID: 31938938
[TBL] [Abstract][Full Text] [Related]
15. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.
Kantor O; Wakeman M; Weiss A; Wong S; Laws A; Grossmith S; Mittendorf EA; King TA
Ann Surg Oncol; 2021 Mar; 28(3):1358-1367. PubMed ID: 32869154
[TBL] [Abstract][Full Text] [Related]
16. Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer.
Ye L; Rünger D; Angarita SA; Hadaya J; Baker JL; Lee MK; Thompson CK; Attai DJ; DiNome ML
Breast Cancer Res Treat; 2022 Jun; 193(2):429-436. PubMed ID: 35389189
[TBL] [Abstract][Full Text] [Related]
17. Axillary lymph node dissection can be omitted in patients with limited clinically node-positive breast cancer: a National Cancer Database analysis.
Cocco D; Shah C; Wei W; Wilkerson A; Grobmyer SR; Al-Hilli Z
Br J Surg; 2022 Nov; 109(12):1293-1299. PubMed ID: 36066266
[TBL] [Abstract][Full Text] [Related]
18. Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
Fu Y; Chung D; Cao MA; Apple S; Chang H
Ann Surg Oncol; 2014 Dec; 21(13):4109-23. PubMed ID: 25081336
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
20. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
